Medscape1mon
Development of Targeted Therapy for Squamous Cell Carcinomas of the Head and Neck
and preclinical studies revealing that IGF-1R is overexpressed in SCCHN, we have yet to find an effective way to exploit this molecular pathway. Results from Phase II head and neck cancer studies ...
Nature1mon
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
Figure 4: IGF-1R antagonism in bovine retinal endothelial cells suppresses subsequent VEGF-activation of the MAP kinase pathway. These data indicate that antagonism of the IGF-1R suppresses ...
The Bakersfield Californian5d
Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer ...
Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of ...
BioWorld4d
Lirum’s LX-101 shows potent antitumoral effects in aggressive tumors
Lirum Therapeutics Inc. has presented data regarding their insulin-like growth factor receptor (IGF-1R) antagonist LX-101, which couples an IGF-1 variant to a cytotoxic methotrexate payload. The ...